“America’s biopharmaceutical researchers and scientists are on the frontlines of cutting edge science bringing new treatments and cures to patients,” said PhRMA president and CEO Stephen J. Ubl.
“I’m excited that our companies will be visiting with members of Congress to share why it’s critical to support pro-innovation policies that continue to allow America to be the leader in biopharmaceutical innovation around the globe,” Ubl added.
The face-to-face meetings will allow members of Congress the opportunity to directly connect with those researchers and scientists developing innovative new treatments and better understand what drives them.
Researchers will also spotlight the progress made by the biopharmaceutical industry in recent years, including efforts to harness the immune system to fight cancer; the discovery of medicines that can cure more than 90 percent of patients with hepatitis C; and the discovery of more than 500 medicines for the 25 million Americans with rare diseases.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.
Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.
To visit PhRMA’s information-packed, consumer-friendly blog about the innovation-driven biopharmaceutical industry, The Catalyst, click here.